Have a feature idea you'd love to see implemented?
Let us know!
CPIX Cumberland Pharmaceuticals Inc
Price (delayed)
$1.08
Market cap
$15.17M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.77
Enterprise value
$19.18M
Cumberland Emerging Technologies, Inc.(www.cet-fund.com)is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University, LaunchTN and WinHealth Pharma. The mission of CET is to bring biomedical technologies and products conceived at
Highlights
CPIX's equity is down by 31% year-on-year and by 6% since the previous quarter
The quick ratio has decreased by 21% QoQ and by 18% YoY
Key stats
What are the main financial stats of CPIX
Market
Valuations
Earnings
Shares outstanding
14.04M
Market cap
$15.17M
Enterprise value
$19.18M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.61
Price to sales (P/S)
0.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.52
Revenue
$36.79M
EBIT
-$10.25M
EBITDA
-$3.92M
Free cash flow
-$1.72M
Per share
Balance sheet
Liquidity
EPS
-$0.77
Free cash flow per share
-$0.12
Book value per share
$1.76
Revenue per share
$2.62
TBVPS
$4.01
Total assets
$76.75M
Total liabilities
$52.28M
Debt
$21.48M
Equity
$24.78M
Working capital
$4.15M
Debt to equity
0.87
Current ratio
1.13
Quick ratio
0.93
Net debt/EBITDA
-1.02
Margins
Efficiency
Dividend
EBITDA margin
-10.7%
Gross margin
83.3%
Net margin
-29.6%
Operating margin
-29.3%
Return on assets
-13.6%
Return on equity
-40.2%
Return on invested capital
-31%
Return on capital employed
-22.4%
Return on sales
-27.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CPIX stock price
How has the Cumberland Pharmaceuticals stock price performed over time
Intraday
-0.92%
1 week
-10%
1 month
-11.48%
1 year
-36.84%
YTD
-39.66%
QTD
-15.63%
Financial performance
How have Cumberland Pharmaceuticals's revenue and profit performed over time
Revenue
$36.79M
Gross profit
$30.65M
Operating income
-$10.77M
Net income
-$10.87M
Gross margin
83.3%
Net margin
-29.6%
The company's operating margin has shrunk by 103% YoY
CPIX's operating income has dropped by 91% year-on-year
The company's net margin fell by 8% QoQ
The revenue has contracted by 6% YoY and by 2.6% from the previous quarter
Growth
What is Cumberland Pharmaceuticals's growth rate over time
Valuation
What is Cumberland Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.61
P/S
0.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.52
Cumberland Pharmaceuticals's EPS has decreased by 5% from the previous quarter
CPIX's P/B is 32% below its 5-year quarterly average of 0.9 and 24% below its last 4 quarters average of 0.8
CPIX's equity is down by 31% year-on-year and by 6% since the previous quarter
The stock's price to sales (P/S) is 59% less than its 5-year quarterly average of 1.0 and 32% less than its last 4 quarters average of 0.6
The revenue has contracted by 6% YoY and by 2.6% from the previous quarter
Efficiency
How efficient is Cumberland Pharmaceuticals business performance
The company's return on equity fell by 16% QoQ
Cumberland Pharmaceuticals's ROS has decreased by 8% from the previous quarter
The ROA has contracted by 8% from the previous quarter
CPIX's return on invested capital is down by 7% since the previous quarter
Dividends
What is CPIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CPIX.
Financial health
How did Cumberland Pharmaceuticals financials performed over time
The total assets is 47% greater than the total liabilities
The current ratio is down by 26% year-on-year and by 22% since the previous quarter
The quick ratio has decreased by 21% QoQ and by 18% YoY
The company's debt is 13% lower than its equity
The debt to equity has soared by 67% YoY and by 6% from the previous quarter
CPIX's equity is down by 31% year-on-year and by 6% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.